Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +75

Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Regeneron (REGN)

AI-generated analysis

πŸ“ˆ Analysts remain bullish on healthcare stocks Viking Therapeutics (VKTX), Regeneron (REGN), and Bausch + Lomb Corporation (BLCO).

πŸ’° Cantor Fitzgerald analyst Steven Seedhouse maintains a Buy rating on VKTX with a $100.00 price target.

πŸ“‰ VKTX shares closed near their 52-week low of $24.41, implying significant upside from current levels.

⭐ The analyst consensus for Viking Therapeutics is Strong Buy with an average target of $93.27.

πŸ’‘ BTIG also maintains a Buy on VKTX with a higher price target of $125.00.

🧬 Truist Financial's Gregory Renza rates Regeneron (REGN) as a Buy with a $796.00 price target.

⚠️ REGN shares are trading near their 52-week low, suggesting potential for a 24.3% upside based on consensus targets.

🏦 Bank of America Securities issued a Buy rating on Regeneron in April with a target of $860.00.

πŸ‘¨β€πŸ’Ό RBC Capital analyst Douglas Miehm gives Bausch + Lomb (BLCO) a Buy rating with a $21.00 price target.

πŸ“Š The general street consensus on BLCO is Hold, averaging an upside of 15.4% from current prices.

πŸ”„ A report in April had TipRanks upgrading BLCO to a Buy with a lower target of $17.50.

πŸ€– Analyst credentials are provided via TipRanks, citing success rates and historical returns for the rating sources.

Bullish Signals
  • Analysts have maintained a Strong Buy consensus on Regeneron (REGN) with an average price target of $876.33, indicating significant upside potential from current trading levels.
  • Bank of America Securities issued a Buy rating on the stock as early as April 22 with a price target of $860.00, demonstrating sustained institutional confidence.
  • Truist Financial analyst Gregory Renza, a 5-star performer with a 45.2% success rate, reaffirmed a Buy rating and set a high price target of $796.00 for Regeneron.
  • Viking Therapeutics (VKTX) has received a Strong Buy consensus with an average price target of $93.27, representing an impressive 188.9% upside from current levels.
  • Multiple analysts including Cantor Fitzgerald and BTIG maintain Buy ratings on Viking Therapeutics with price targets ranging from $100.00 to $125.00.
  • Analysts are optimistic about the advancement of VK2735 through Phase 3 trials for Viking Therapeutics, driving bullish sentiment ahead of earnings.
Risk Factors
  • The share price of Viking Therapeutics (VKTX) is trading near its 52-week low of $24.41, indicating significant underperformance despite bullish analyst sentiment.
  • The analyst consensus for Bausch + Lomb Corporation suggests a Hold rating, which contradicts the recent upgrade to Buy by TipRanks, creating uncertainty around future valuation targets.
  • Viking Therapeutics reported Q1 EPS of $1.37 against a consensus estimate of 91 cents, implying potential earnings volatility or market overreaction given the options imply only a 7.0% move post-earnings.
Full Analysis
Analysts have expressed bullish sentiment toward several healthcare stocks, with significant focus on Viking Therapeutics (VKTX) and Regeneron (REGN). Cantor Fitzgerald analyst Steven Seedhouse maintained a Buy rating on Viking Therapeutics and set a price target of $100.00, noting the company's shares closed last Wednesday at $31.33, near its 52-week low of $24.41. TipRanks data identifies Seedhouse as a 4-star analyst with an average return of 10.9% and a 44.3% success rate. The current analyst consensus for Viking Therapeutics is a Strong Buy with an average price target of $93.27, implying 188.9% upside from current levels. Additionally, BTIG maintained a Buy rating with a $125.00 price target. Gregory Renza from Truist Financial also issued a Buy rating on Regeneron today with a price target of $796.00, based on shares that closed last Wednesday at $686.36, close to the 52-week low of $629.02. Renza is a 5-star analyst according to TipRanks with an average return of 16.8% and a 45.2% success rate. The consensus on Regeneron remains Strong Buy with an average price target of $876.33, representing 24.3% upside from current levels. Earlier support for Regeneron includes a report issued on April 22 by Bank of America Securities, which maintained a Buy rating with a $860.00 price target. In contrast to the bullish outlook for VKTX and REGN, coverage for Bausch + Lomb Corporation (BLCO) presents a mixed picture. RBC Capital analyst Douglas Miehm maintained a Buy rating today and set a price target of $21.00, with shares closing last Wednesday at $15.34. Miehm is rated 4 stars by TipRanks with an average return of 3.9% and a 48.5% success rate. However, the general street consensus for Bausch + Lomb is currently a Hold with an average price target of $18.55, which represents a 15.4% upside. Prior to this, a report issued on April 24 indicated an upgrade to Buy with a $17.50 price target, though the current analyst consensus leans toward holding positions given the volatility associated with CNR shares and broader market considerations mentioned in related commentary.